Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company
creating innovative personalized therapeutics for patients with
genetically defined cancers, reported pre-clinical data and early
clinical observations from an ongoing Phase 1 trial, being conducted in
collaboration with Eisai, the Institut Gustave Roussy, and the Institut
Bergonie, of EZH2 inhibitor EPZ-6438 (E7438) in patients with advanced
solid tumors and B-cell lymphomas.
for Epizyme Presents Pre-Clinical Data and Early Clinical Observations from Ongoing Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) at ASH Meeting on Lymphoma Biology investment picks